Fig. 7

Rolapitant inhibits lung cancer cell growth in vivo. A Twenty-four nude mice with visible tumors were randomly assigned to 3 groups: control, Rolapitant (50 mg/kg) and Rolapitant (75 mg/kg). Pictures showed the tumors of all the 24 cases both in control and treatment groups. Tumor volume and weight were measured every 3 days for up to 22 days. B Body weight was recorded every 3 days for up to 22 days. C Immunohistochemistry illustrated the level of Ki67, Cleaved-Caspase-8, Cleaved-Caspase-3, DR5 and GRP78 in tumor issues containing model and treatment groups. Scale bar: 15 μm. D A549 and H460 cells were treated with DMSO, Rolapitant (10 μM), Afatinib (5 μM), Gefifinib (5 μM), Rolapitant plus Afatinib or Rolapitant plus Gefifinib and then assessed for OD value (450 nm) using CCK-8 assays. E Thirty-six nude mice with visible tumors were randomly assigned to 6 groups: control, 50 mg/kg Rolapitant, 20 mg/kg Gefitinib, 4 mg/kg Afatinib, 50 mg/kg Rolapitant plus 20 mg/kg Gefitinib, 50 mg/kg Rolapitant plus 4 mg/kg Afatinib. Pictures showed the tumors of all the 36 cases both in control, treatment groups and combined treatment groups. F Tumor volume and weight were measured every 3 days for up to 22 days. G Body weight was recorded every 3 days for up to 22 days. All the results were presented as the mean ± SD. (*p < 0.05, **p < 0.01, ***p < 0.001, ns = no significance, vs. Control)